volume 18 endocrine–related...

Endocrine – Related

Cancer

Volume 18

ISSN 1351–0088 (print)ISSN 1479–6821 (online)

Editor-in-Chief

Associate Editors

Editorial Board

Founding Editor

Statistical Advisor

C EngCleveland, OH, USA

C L ClarkeSydney, Australia

D BallBaltimore, MD, USA

R ClarkeWashington, DC, USA

D El-AshryMiami, FL, USA

O GimmLinkoping, Sweden

C A LangeMinneapolis, MN, USA

C J McCabeBirmingham, UK

B RobinsonSydney, Australia

J TrapmanRotterdam, Netherlands

M van de VijverAmsterdam, Netherlands

R WeigelIowa City, IA, USA

M XingBaltimore, MD, USA

V H T JamesLondon, UK

H van den BergCoventry, UK

A B GrossmanLondon, UK

N BundredManchester, UK

A Di CristofanoNew York, NY, USA

R EliseiPisa, Italy

B HaugenAurora, CO, USA

S K LibuttiNew York, NY, USA

S OesterreichHouston, TX, USA

P SantistebanMadrid, Spain

W TilleyAdelaide, Australia

P WebbBrisbane, Australia

B WiedenmannBerlin, Germany

K KnudsenPhiladelphia, PA, USA

F ClaessensLeuven, Belgium

M DicklerNew York, NY, USA

P GhoshSacramento, CA, USA

W W de HerderRotterdam, Netherlands

D MarshSt Leonards, Australia

M C PikeLos Angeles, CA, USA

M SantoroNaples, Italy

R VigneriCatania, Italy

F WeberEssen, Germany

J WimalasenaKnoxville, TN, USA

Endocrine-Related Cancer is published by

BioScientifica (Limited by Guarantee).

The agent for distribution is Portland Press, PO Box 32,

Commerce Way, Whitehall Industrial Estate,

Colchester CO2 8HP, UK.

Copyright q2011 by the Society for Endocrinology.

Typeset by OKS Prepress Services, Chennai, India.

Printed by Latimer Trend & Company Ltd, Plymouth, UK.

Printed on acid-free paper.

Endocrine – Related

Cancer

Volume contents

Number 1 $ February 2011

EDITORIAL: Something old, somethingnew

Charis Eng E1

COMMENTARY: Adrenomedullin andcalcitonin gene-related peptide receptors inendocrine-related cancers: opportunitiesand challenges

Debbie L Hay, Christopher S Walker& David R Poyner

C1–C14

REVIEW: Clinical significance of estrogenreceptor phosphorylation

Leigh C Murphy, Srinivas V Seekallu& Peter H Watson

R1–R14

The tyrosine kinase inhibitor ZD6474blocks proliferation of RET mutantmedullary thyroid carcinoma cells

Donata Vitagliano, Valentina DeFalco, Anna Tamburrino, SabrinaColuzzi, Giancarlo Troncone, GennaroChiappetta, Fortunato Ciardiello,Giampaolo Tortora, James A Fagin,Anderson J Ryan, Francesca Carlomagno& Massimo Santoro

1–11

FSH inhibits ovarian cancer cell apoptosisby up-regulating survivin and down-regulating PDCD6 and DR5

Yan Huang, Hongyan Jin, Yingtao Liu,Jiayi Zhou, Jingxin Ding, Kwai WaCheng, Yinhua Yu & Youji Feng

13–26

Single photon emission computedtomography imaging for temporaldynamics of thyroidal and salivaryradionuclide accumulation in 17-allyamino-17-demothoxygeldanamycin-treated thyroid cancer mouse model

Yu-Yu Liu, Michael P Brandt, Daniel HShen, Richard T Kloos, Xiaoli Zhang &Sissy M Jhiang

27–37

2011

Volume 18

ISSN 1351–0088 (print)ISSN 1479–6821 (online)

Expression of neuregulin 4 splice variantsin normal human tissues and prostate cancerand their effects on cell motility

Nandini V L Hayes, Edith Blackburn,Mary M Boyle, Graham A Russell, TeresaM Frost, Byron J T Morgan & William JGullick

39–49

Ki-67 index, tumor differentiation, andextent of liver involvement are independentprognostic factors in patients with livermetastases of digestive endocrinecarcinomas

O Hentic, A Couvelard, V Rebours,M Zappa, S Dokmak, P Hammel,F Maire, D O’Toole, P Levy,A Sauvanet & P Ruszniewski

51–59

Expression of connective tissue growthfactor and IGF1 in normal and neoplasticgastrointestinal neuroendocrine cells andtheir clinico-pathological significance

Gregory A Kaltsas, Janet L Cunningham,Sture E Falkmer, Lars Grimelius &Apostolos V Tsolakis

61–71

Mutation analysis of HIF prolylhydroxylases (PHD/EGLN) in individualswith features of phaeochromocytoma andrenal cell carcinoma susceptibility

Dewi Astuti, Christopher J Ricketts,Rasheduzzaman Chowdhury, Michael AMcDonough, Dean Gentle, Gail Kirby,Susanne Schlisio, Rajappa S Kenchappa,Bruce D Carter, William G Kaelin Jr,Peter J Ratcliffe, Christopher J Schofield,Farida Latif & Eamonn R Maher

73–83

The miR-200 family controls b-tubulin IIIexpression and is associated withpaclitaxel-based treatment response andprogression-free survival in ovarian cancerpatients

Susanna Leskela, Luis J Leandro-Garcıa,Marta Mendiola, Jorge Barriuso, LucıaInglada-Perez, Ivan Munoz, BeatrizMartınez-Delgado, Andres Redondo,Javier de Santiago, Mercedes Robledo,David Hardisson &Cristina Rodrıguez-Antona

85–95

Catecholamine metabolomic and secretoryphenotypes in phaeochromocytoma

Graeme Eisenhofer, Karel Pacak,Thanh-Truc Huynh, Nan Qin, GennadyBratslavsky, W Marston Linehan,Massimo Mannelli, Peter Friberg, StefanK Grebe, Henri J Timmers, Stefan RBornstein & Jacques W M Lenders

97–111

Distinctive functions of p160 steroidreceptor coactivators in proliferation of anestrogen-independent, tamoxifen-resistantbreast cancer cell line

Sudipan Karmakar, Estrella A Foster,Julia K Blackmore & Carolyn L Smith

113–127

AZD1152 negatively affects the growth ofanaplastic thyroid carcinoma cells andenhances the effects of oncolytic virusdl922-947

Silvana Libertini, Antonella Abagnale,Carmela Passaro, Ginevra Botta, SaraBarbato, Paolo Chieffi & GiuseppePortella

129–141

www.endocrinology-journals.org

Increased uptake of [123I]meta-iodobenzylguanidine, [18F]fluorodopamine,and [3H]norepinephrine in mousepheochromocytoma cells and tumors aftertreatment with the histone deacetylaseinhibitors

Lucia Martiniova, Shiromi M Perera,Frederieke M Brouwers, Salvatore Alesci,Mones Abu-Asab, Amanda F Marvelle,Dale O Kiesewetter, David Thomasson,John C Morris, Richard Kvetnansky,Arthur S Tischler, James C Reynolds,Antonio Tito Fojo & Karel Pacak

143–157

Do histological, immunohistochemical,and metabolic (radioiodine andfluorodeoxyglucose uptakes) patterns ofmetastatic thyroid cancer correlate withatient outcome?

D Deandreis, A Al Ghuzlan,S Leboulleux, L Lacroix, J P Garsi,M Talbot, J Lumbroso, E Baudin,B Caillou, J M Bidart & M Schlumberger

159–169

A pilot genome-wide association studyshows genomic variants enriched in thenon-tumor cells of patients with well-differentiated neuroendocrine tumors ofthe ileum

Kyle M Walsh, Murim Choi, Kjell Oberg,Matthew H Kulke, James C Yao,Chengqing Wu, Magdalena Jurkiewicz,Ling-I Hsu, Susanne M Hooshmand,Manal Hassan, Eva T Janson, Janet LCunningham, Evan Vosburgh, Richard SSackler, Richard P Lifton, Andrew TDeWan & Josephine Hoh

171–180

mTOR expression and activity patterns ingastroenteropancreatic neuroendocrinetumours

Atsuko Kasajima, Marianne Pavel, SilviaDarb-Esfahani, Aurelia Noske, AlbrechtStenzinger, Hironobu Sasano, ManfredDietel, Carsten Denkert, ChristophRocken, Bertram Wiedenmann &Wilko Weichert

181–192

Gene expression signature discriminatessporadic from post-radiotherapy-inducedthyroid tumors

Catherine Ory, Nicolas Ugolin, CelineLevalois, Ludovic Lacroix, BernardCaillou, Jean-Michel Bidart, MartinSchlumberger, Ibrahima Diallo, Florentde Vathaire, Paul Hofman,Jose Santini, Bernard Malfoy &Sylvie Chevillard

193–206

Number 2 $ April 2011

REVIEW: Transcriptome analysis ofadrenocortical cancers: from molecularclassification to the identification of newtreatments

Bruno Ragazzon, Guillaume Assie &Jerome Bertherat

R15–R27


REVIEW: Persistent disease and recurrencein differentiated thyroid cancer patientswith undetectable postoperative stimulatedthyroglobulin level

C Nascimento, I Borget,A Al Ghuzlan, D Deandreis,L Chami, J P Travagli, D Hartl,J Lumbroso, C Chougnet, L Lacroix,E Baudin, M Schlumberger& S Leboulleux

R29–R40

Inhibition of the Rho GTPase, Rac1,decreases estrogen receptor levels and is anovel therapeutic strategy in breast cancer

Adena E Rosenblatt, Maria Ines Garcia,Leah Lyons, Yingqiu Xie, CarolMaiorino, Laurent Desire, JoyceSlingerland & Kerry L Burnstein

207–219

Decreased progesterone receptor isoformexpression in luteal phase fallopian tubeepithelium and high-grade serouscarcinoma

Alicia A Tone, Carl Virtanen, PatriciaA Shaw & Theodore J Brown

221–234

IGF1 and risk of additional breast cancer inthe WHEL study

Wael K Al-Delaimy, Shirley W Flatt,Loki Natarajan, Gail A Laughlin,Cheryl L Rock, Ellen B Gold,Bette J Caan, Barbara A Parker& John P Pierce

235–244

Androgen receptor levels are upregulatedby Akt in prostate cancer

Susan Ha, Rachel Ruoff, Nicole Kahoud,Thomas F Franke & Susan K Logan

245–255

Combination of trastuzumab and letrozoleafter resistance to sequential trastuzumaband aromatase inhibitor monotherapies inpatients with estrogen receptor-positive,HER-2-positive advanced breast cancer:a proof-of-concept trial (SAKK 23/03)

D Koeberle, T Ruhstaller, L Jost,O Pagani, K Zaman, R von Moos,C Oehlschlegel, S Crowe, C Pilop,B Thuerlimann & on behalf of the SwissGroup for Clinical Cancer Research(SAKK)

257–264

Association of genetic polymorphisms inESR2, HSD17B1, ABCB1, and SHBG geneswith colorectal cancer risk

J Sainz, A Rudolph, R Hein,M Hoffmeister, S Buch, W von Schonfels,J Hampe, C Schafmayer, H Volzke,B Frank, H Brenner, A Forsti,K Hemminki & J Chang-Claude

265–276

The novel Raf inhibitor Raf265 decreasesBcl-2 levels and confers TRAIL-sensitivityto neuroendocrine tumour cells

Kathrin Zitzmann, Enrico de Toni,Janina von Ruden, Stephan Brand,Burkhard Goke, Rudiger P Laubender& Christoph J Auernhammer

277–285

Expression of somatostatin receptors,dopamine D2 receptors, noradrenalinetransporters, and vesicular monoaminetransporters in 52 pheochromocytomasand paragangliomas

Alexandru Saveanu, Mihaela Muresan,Catherine De Micco, David Taieb,Anne-Laure Germanetti, Frederic Sebag,Jean-Francois Henry, Laurent Brunaud,Alain Enjalbert, Georges Weryha &Anne Barlier

287–300


Number 3 $ June 2011

COMMENTARY: mTOR inhibition, apotential novel approach for bronchialcarcinoids

Mei Dong & James C Yao C15–C18

REVIEW: Novel insights on imaging sexhormone-dependent tumourigenesis in vivo

Balaji Ramachandran, Alessia Stell,Luca Maravigna, Adriana Maggi& Paolo Ciana

R41–R51

REVIEW: Tumor-induced osteomalacia William H Chong, Alfredo A Molinolo,Clara C Chen & Michael T Collins

R53–R77

REVIEW: A critical evaluation of the roleof aromatase inhibitors as adjuvant therapyfor postmenopausal women with breastcancer

Thierry Petit, Patrick Dufour& Ian Tannock

R79–R89

Histone deacetylase inhibitors upregulateRap1GAP and inhibit Rap activity inthyroid tumor cells

Xiaoyun Dong, Christopher Korch& Judy L Meinkoth

301–310

Coxsackie and adenovirus receptor is atarget and a mediator of estrogen action inbreast cancer

David Vindrieux, Ludovic Le Corre,Jer-Tsong Hsieh, Raphael Metivier,Pauline Escobar, Andres Caicedo,Madly Brigitte & Gwendal Lazennec

311–321

Overexpression of the natural antisensehypoxia-inducible factor-1a transcript isassociated with malignantpheochromocytoma/paraganglioma

P N Span, J U Rao,S B J Oude Ophuis, J W M Lenders,F C G J Sweep, P Wesseling,B Kusters, F H van Nederveen,R R de Krijger, A R M M Hermus& H J L M Timmers

323–331

Therapeutically activating RB:reestablishing cell cycle control inendocrine therapy-resistant breast cancer

Chellappagounder Thangavel,Jeffry L Dean, Adam Ertel,Karen E Knudsen, C Marcelo Aldaz,Agnieszka K Witkiewicz,Robert Clarke & Erik S Knudsen

333–345

Hyperplasia–adenoma sequence in pituitarytumorigenesis related to aryl hydrocarbonreceptor interacting protein gene mutation

Chiara Villa, Maria Stefania Lagonigro,Flavia Magri, Maria Koziak,Marie-Lise Jaffrain-Rea, Raja Brauner,Jerome Bouligand, Marie Pierre Junier,Federico Di Rocco, Christian Sainte-Rose,Albert Beckers, Francois Xavier Roux,Adrian F Daly & Luca Chiovato

347–356


Changes in insulin resistance indicators,IGFs, and adipokines in a year-long trial ofaerobic exercise in postmenopausal women

Christine M Friedenreich,Heather K Neilson, Christy G Woolcott,Anne McTiernan, Qinggang Wang,Rachel Ballard-Barbash,Charlotte A Jones, Frank Z Stanczyk,Rollin F Brant, Yutaka Yasui, Melinda LIrwin, Kristin L Campbell,Margaret L McNeely, Kristina H Karvinen& Kerry S Courneya

357–369

Modification of menopausal hormonetherapy-associated colorectal cancer risk bypolymorphisms in sex steroid signaling,metabolism and transport related genes

Anja Rudolph, Juan Sainz,Rebecca Hein, Michael Hoffmeister,Bernd Frank, Asta Forsti,Hermann Brenner, Kari Hemminki &Jenny Chang-Claude

371–384

Number 4 $ August 2011

COMMENTARY: Killing the secondmessenger: targeting loss of cell cyclecontrol in endocrine-resistant breast cancer

Carol A Lange & Douglas Yee C19–C24

COMMENTARY: Leptin and cancer: fromcancer stem cells to metastasis

Jiyoung Park & Philipp E Scherer C25–C29

REVIEW: The RNA-binding proteinSam68 is a multifunctional player in humancancer

Pamela Bielli, Roberta Busa, Maria PaolaParonetto & Claudio Sette

R91–R102

REVIEW: Pathways of chemotherapyresistance in castration-resistant prostatecancer

Kate L Mahon, Susan M Henshall,Robert L Sutherland & Lisa G Horvath

R103–R123

REVIEW: Insulin receptor and cancer Antonino Belfiore & RobertaMalaguarnera

R125–R147

The TORC1/TORC2 inhibitor, Palomid529, reduces tumor growth and sensitizes todocetaxel and cisplatin in aggressive andhormone-refractory prostate cancer cells

Giovanni Luca Gravina, FrancescoMarampon, Foteini Petini,Leda Biordi, David Sherris, EmmanueleA Jannini, Vincenzo Tombolini &Claudio Festuccia

385–400

In vitro transforming potential, intracellularsignaling properties, and sensitivity to akinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu,and Arg886Trp

Hugo Prazeres, Joana P Couto, FernandoRodrigues, Joao Vinagre, Joana Torres,Vitor Trovisco, Teresa C Martins, ManuelSobrinho-Simoes & Paula Soares

401–412


Survivin upregulation, dependent onleptin–EGFR–Notch1 axis, is essentialfor leptin-induced migration of breastcarcinoma cells

Brandi B Knight, Gabriela MOprea-Ilies, Arumugam Nagalingam,Lily Yang, Cynthia Cohen,Neeraj K Saxena & Dipali Sharma

413–428

Hashimoto’s thyroiditis is associated withpapillary thyroid carcinoma: role of TSHand of treatment with L-thyroxine

E Fiore, T Rago, F Latrofa,M A Provenzale, P Piaggi,A Delitala, M Scutari, F Basolo,G Di Coscio, L Grasso, A Pinchera &P Vitti

429–437

Targeting protein kinase C by Enzastaurinrestrains proliferation and secretion inhuman pancreatic endocrine tumors

Daniela Mole, Teresa Gagliano,Erica Gentilin, Federico Tagliati,Claudio Pasquali, Maria RosariaAmbrosio, Giancarlo Pansini,Ettore C degli Uberti &Maria Chiara Zatelli

439–450

Dihydrotestosterone upregulates theexpression of epidermal growth factorreceptor and ERBB2 in androgen receptor-positive bladder cancer cells

Yichun Zheng, Koji Izumi,Jorge L Yao & Hiroshi Miyamoto

451–464

Novel candidate colorectal cancerbiomarkers identified by methylationmicroarray-based scanning

Yuriko Mori, Alexandru V Olaru, YulanCheng, Rachana Agarwal, Jian Yang,Delgermaa Luvsanjav, Wayne Yu, FlorinM Selaru, Susan Hutfless, Mark Lazarev,John H Kwon, Steven R Brant,Michael R Marohn, David F Hutcheon,Mark D Duncan, Ajay Goel &Stephen J Meltzer

465–478

Different gene expression profiles inmetastasizing midgut carcinoid tumors

Katarina Edfeldt, Peyman Bjorklund,Goran Akerstrom, Gunnar Westin,Per Hellman & Peter Stalberg

479–489

Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese miceand abrogates tumor initiating cell survival

Qiao Zheng, Sarah M Dunlap, JinlingZhu, Erinn Downs-Kelly, Jeremy Rich,Stephen D Hursting, Nathan A Berger &Ofer Reizes

491–503

Y-box binding protein-1 promotescastration-resistant prostate cancer growthvia androgen receptor expression

Masaki Shiota, Ario Takeuchi,YooHyun Song, Akira Yokomizo,Eiji Kashiwagi, Takeshi Uchiumi,Kentaro Kuroiwa, Katsunori Tatsugami,Naohiro Fujimoto, Yoshinao Oda &Seiji Naito

505–517


Functional characterization of the MTC-associated germline RET-K666E mutation:evidence of oncogenic potential enhancedby the G691S polymorphism

Maria Grazia Borrello, Antonella Aiello,Bernard Peissel, Maria Grazia Rizzetti,Piera Mondellini, Debora Degl’Innocenti,Veronica Catalano, Morena Gobbo, PaolaCollini, Italia Bongarzone,Marco A Pierotti, Angela Greco& Ettore Seregni

519–527

Antineoplastic effect of iodine and iodide indimethylbenz[a]anthracene-inducedmammary tumors: association betweenlactoperoxidase and estrogen-adductproduction

Ofelia Soriano, Guadalupe Delgado,Brenda Anguiano, Pavel Petrosyan,Edith D Molina-Servın,Maria E Gonsebatt & Carmen Aceves

529–539

Number 5 $ October 2011

REVIEW: Hooked on zebrafish: insightsinto development and cancer of endocrinetissues

Caitlin Bourque & Yariv Houvras R149–R164

REVIEW: Rare metastases of differentiatedthyroidcarcinoma: pictorial review

Hong-Jun Song, Yan-Li Xue,Yan-Hong Xu, Zhong-Ling Qiu& Quan-Yong Luo

R165–R174

REVIEW: Intratumoral androgenbiosynthesis in prostate cancerpathogenesis and response to therapy

Changmeng Cai & Steven P Balk R175–R182

Alternatively spliced androgen receptorvariants

Scott M Dehm & Donald J Tindall R183–R196

Src kinase activity coordinates celladhesion and spreading with activation ofmammalian target of rapamycin inpancreatic endocrine tumour cells

Alessia Di Florio, Laura Adesso, SimonaPedrotti, Gabriele Capurso, EmanuelaPilozzi, Vincenzo Corbo, Aldo Scarpa,Raffaele Geremia, Gianfranco Delle Fave& Claudio Sette

541–554

The role of FOXO3 in DNA damageresponse in thyrocytes

Antje Klagge, Carl Weidinger, KerstinKrause, Beate Jessnitzer, MonikaGutknecht & Dagmar Fuhrer

555–564

Changes in breast cancer biomarkers in theIGF1R/PI3K pathway in recurrent breastcancer after tamoxifen treatment

S C Drury, S Detre, A Leary,J Salter, J Reis-Filho, V Barbashina,C Marchio, E Lopez-Knowles,Z Ghazoui, K Habben, S Arbogast,S Johnston & M Dowsett

565–577


Can the microRNA signature distinguishbetween thyroid tumors of uncertainmalignant potential and other well-differentiated tumors of the thyroid gland?

Sandra Lassalle, Veronique Hofman,Marius Ilie, Christelle Bonnetaud,Marie-Pierre Puissegur, Patrick Brest,Celine Loubatier, Nicolas Guevara,Olivier Bordone, Bruno Cardinaud,Kevin Lebrigand, Geraldine Rios,Joseph Santini, Brigitte Franc,Bernard Mari, Abir Al Ghuzlan,Philippe Vielh, Pascal Barbry &Paul Hofman

579–594

Hepatic arterial infusion enhancesDOTATOC radiopeptide therapy inpatients with neuroendocrine livermetastases

Clemens Kratochwil, RubenLopez-Benıtez, Walter Mier,Sabine Haufe, Berend Isermann,Hans-Ulrich Kauczor,Peter L Choyke, Uwe Haberkorn& Frederik L Giesel

595–602

In silico and in vitro analysis of raregermline allelic variants of RET oncogeneassociated with medullary thyroid cancer

B Cosci, A Vivaldi, C Romei,F Gemignani, S Landi, R Ciampi,A Tacito, E Molinaro, L Agate,V Bottici, V Cappagli, D Viola,P Piaggi, P Vitti, A Pinchera& R Elisei

603–612

Inhibition of gap junction transfer sensitizesthyroid cancer cells to anoikis

Kirk Jensen, Aneeta Patel,Joanna Klubo-Gwiezdzinska,Andrew Bauer & Vasyl Vasko

613–626

The impact of ovulation on fallopian tubeepithelial cells: evaluating three hypothesesconnecting ovulation and serous ovariancancer

Shelby M King, Tyvette S Hilliard,Lucia Y Wu, Randal C Jaffe,Asgerally T Fazleabas &Joanna E Burdette

627–642

Erratum X1

Number Supplement 1 $ October 2011

EDITORIAL: Neuroendocrine tumors:recent progress in diagnosis and treatment

Kjell Oberg E3–E6

Classification and pathology ofgastroenteropancreatic neuroendocrineneoplasms

Gunter Kloppel S1–S16


Circulating biomarkers in gastroenteropan-creatic neuroendocrine tumours

Kjell Oberg S17–S25

Nuclear medicine techniques for theimaging and treatment of neuroendocrinetumours

Jaap J M Teunissen,Dik J Kwekkeboom, R Valkema& Eric P Krenning

S27–S51

Therapeutic management of patients withgastroenteropancreatic neuroendocrinetumours

Mohid S Khan & Martyn E Caplin S53–S74

Number 6 $ December 2011

COMMENTARY: Quantitative validationof GJC1 promoter hypermethylation inbenign and malignant colorectal tumors

Deeqa Ahmed, Ragnhild A Lothe,Edgar Rivedal & Guro E Lind

C31–C34

REVIEW: Expression and function of ErbBreceptors and ligands in the pituitary

Odelia Cooper, George Vlotides,Hidenori Fukuoka, Mark I Greene& Shlomo Melmed

R197–R211

REVIEW: Neuroblastoma therapy: what isin the pipeline?

Carla S Verissimo, Jan J Molenaar,Carlos P Fitzsimons & Erno Vreugdenhil

R213–R231

REVIEW: The role of somatostatin anddopamine D2 receptors in endocrine tumors

Federico Gatto & Leo J Hofland R233–R251

REVIEW: Genetics and clinicalcharacteristics of hereditarypheochromocytomas and paragangliomas

Jenny Welander, Peter Soderkvist& Oliver Gimm

R253–R276

The role of microRNA deregulation in thepathogenesis of adrenocortical carcinoma

Deniz M Ozata, Stefano Caramuta, DavidVelazquez-Fernandez, Pinar Akcakaya,Hong Xie, Anders Hoog, Jan Zedenius,Martin Backdahl, Catharina Larsson &Weng-Onn Lui

643–655

Knockdown of survivin (BIRC5) causesapoptosis in neuroblastoma via mitoticcatastrophe

Fieke Lamers, Ida van der Ploeg,Linda Schild, Marli E Ebus, Jan Koster,Bo R Hansen, Troels Koch,Rogier Versteeg, Huib N Caron &Jan J Molenaar

657–668


BRAFV600E mutation, TIMP-1upregulation, and NF-kB activation:closing the loop on the papillary thyroidcancer trilogy

Alessandra Bommarito, Pierina Richiusa,Elvira Carissimi, Giuseppe Pizzolanti,Vito Rodolico, Giovanni Zito, AngelaCriscimanna, Francesco Di Blasi, MariaPitrone, Monica Zerilli, Marco C Amato,Gaetano Spinelli, Valeria Carina,Giuseppe Modica, M Adelfio Latteri,Aldo Galluzzo & Carla Giordano

669–685

Genome-wide alterations in genemethylation by the BRAF V600E mutationin papillary thyroid cancer cells

Peng Hou, Dingxie Liu &Mingzhao Xing

687–697

IGF1/insulin receptor kinase inhibition byBMS-536924 is better tolerated thanalloxan-induced hypoinsulinemia and moreeffective than metformin in the treatment ofexperimental insulin-responsive breastcancer

Carly Jade Dool, Haider Mashhedi,Mahvash Zakikhani, Stephanie David,Yunhua Zhao, Elena Birman, Joan MCarboni, Marco Gottardis, Marie-JoseBlouin & Michael Pollak

699–709

MiR-129-5p is required for histonedeacetylase inhibitor-induced cell death inthyroid cancer cells

Patrick Brest, Sandra Lassalle, VeroniqueHofman, Olivier Bordone, VirginieGavric Tanga, Christelle Bonnetaud,Chimene Moreilhon, Geraldine Rios,Jose Santini, Pascal Barbry, CatharinaSvanborg, Baharia Mograbi, BernardMari & Paul Hofman

711–719

Low residual proliferation after short-termletrozole therapy is an early predictivemarker of response in high proliferativeER-positive breast cancer

Philippe L Bedard, Sandeep K Singhal,Michail Ignatiadis, Ian Bradbury,Benjamin Haibe-Kains, ChristineDesmedt, Sherene Loi, Dean B Evans,Stefan Michiels, J Michael Dixon,William R Miller, Martine J Piccart &Christos Sotiriou

721–730

CDC23 regulates cancer cell phenotype andis overexpressed in papillary thyroid cancer

Lisa Zhang, Reza Rahbari, Mei He &Electron Kebebew

731–742

Evidence of oncogene-induced senescencein thyroid carcinogenesis

Maria Grazia Vizioli, Patricia A Possik,Eva Tarantino, Katrin Meissl,Maria Grazia Borrello, Claudia Miranda,Maria Chiara Anania, Sonia Pagliardini,Ettore Seregni, Marco A Pierotti,Silvana Pilotti, Daniel S Peeper& Angela Greco

743–757

Protein kinase Cd inactivation inhibitscellular proliferation and decreases survivalin human neuroendocrine tumors

Zhihong Chen, Lora W Forman,Kenneth A Miller, Brandon English,Asami Takashima, Regine A Bohacek,Robert M Williams & Douglas V Faller

759–771


Total oxidant/antioxidant status in sera ofpatients with thyroid cancers

Dong Wang, Jia-Fu Feng,Ping Zeng, Yun-Hong Yang,Jun Luo & Yu-Wei Yang

773–782

Apoptosis gene signature of Survivin andits splice variant expression in breastcarcinoma

Frederique Vegran, Romain Boidot,Franck Bonnetain, Muriel Cadouot,Sandy Chevrier & Sarab Lizard-Nacol

783–792

LETTER TO THE EDITOR: Diagnosticaccuracy and clinical significance of thefine needle aspiration Ki-67 labelling indexin pancreatic endocrine tumours

Michail Kaklamanos, IoannisKaroumpalis, Charitini Salla, DimitriosThomas, George Kanakis, KrystalleniaAlexandraki, Stavros Sougioultzis,Evanthia Diakatou, George Kontogeorgos& Gregory Kaltsas

L1–L3

ERRATUM: Can the microRNA signaturedistinguish between thyroid tumors ofuncertain malignant potential and otherwell-differentiated tumors of the thyroidgland?

Sandra Lassalle, Veronique Hofman,Marius Ilie, Christelle Bonnetaud,Marie-Pierre Puissegur, Patrick Brest,Celine Loubatier, Nicolas Guevara,Olivier Bordone, Bruno Cardinaud,Kevin Lebrigand, Geraldine Rios,Joseph Santini, Brigitte Franc,Bernard Mari, Abir Al Ghuzlan,Philippe Vielh, Pascal Barbry &Paul Hofman

X3


Endocrine -Related Cancer

• Cellular and Molecular Biology of Hormones and Growth Factors Pathogenetic in Cancer

• Hormone-Dependent Neoplasms• Hormonal Carcinogenesis

DECEMBER 2011Volume 18Issue 6ISSN 1351-0088 (print)ISSN 1479-6821 (online)

Endocrine-Related CancerVolum

e 18Num

ber 6Decem

ber 2011Pages R000–R000, 000–000, X1

1351-0088(201112)18:6;1-7

ERC 18_6_cover.qxp 10/20/11 6:18 PM Page 1

volume 18 endocrine–related...

Documents